#Canada #Toronto #AI Technology #Perimeter Medical #Michelle Caron

Perimeter Medical Imaging AI Welcomes Michelle Caron to Its Board of Directors

Perimeter Medical Imaging AI, Inc., a medical technology company transitioning into the commercial phase, is thrilled to announce the appointment of Michelle Caron as a member of its Board of Directors, effective immediately. This strategic addition is set against the backdrop of a pivotal phase in the company’s growth strategy, propelled by its innovative AI-enabled technology, Claire™.

A Strong Addition to the Team

Adrian Mendes, the CEO of Perimeter, expressed his enthusiasm about Caron's entry into the board. He noted her impressive leadership in finance, particularly her current role as CFO at A10 Networks, and significant past contributions at Danaher Corporation's life sciences segment. Mendes remarked, "Her vast experience in financial leadership will be invaluable as we continue to expand our commercial efforts and enhance our AI technologies."

Michelle Caron brings over 28 years of extensive experience in financial operations to Perimeter. Before her role at A10 Networks, she held senior finance positions at Beckman Coulter Life Sciences, Pall, and Phenomenex, all under the umbrella of Danaher Corporation. Her background also includes significant roles at Philips Healthcare and Stryker Biotech, showcasing a career steeped in commercial and operational finance.

Caron, a Certified Public Accountant, holds an MBA from Southern Connecticut State University and a Bachelor's degree in Accounting from Central Connecticut State University. She expressed her excitement in joining Perimeter, stating, "This is a crucial time for the company, and I look forward to using my expertise in finance to support Perimeter’s growth and the advancement of its innovative technology."

Advancements in Cancer Surgery

Based in Toronto and Dallas, Perimeter Medical Imaging AI is on a mission to revolutionize cancer surgery by utilizing advanced, real-time imaging tools that address significant unmet medical needs. One of its flagship products, Claire™, has recently gained approval from the FDA and promises to enhance surgical accuracy by providing ultra-high-resolution imaging for better tumor margin assessment.

The Claire OCT System complements current surgical methods by offering three-dimensional imaging that allows for real-time visualization. It integrates artificial intelligence to identify and mark areas of concern during procedures, contributing to more successful outcomes in patients diagnosed with breast cancer. It is designed to aid surgeons in making informed decisions without replacing standard histopathological assessments.

The introduction of Michelle Caron to the board signifies Perimeter's commitment to leveraging top-tier expertise as it navigates through this transformative phase. With her robust background in finance and operations, the company is poised to enhance its strategic direction, ultimately benefiting its mission to improve cancer surgery outcomes.

In navigating through a crucial period, Perimeter Medical Imaging AI is keen on fostering innovations that not only meet regulatory standards but also deliver real-world value to surgeons and patients alike. Caron’s financial acumen will aid in aligning the company’s resources to maximize its growth trajectory and strengthen its market position.

The Road Ahead

As Perimeter embarks on its journey of innovation and commercialization with Caron on board, stakeholders can expect a focused approach towards achieving ambitious goals in technology advancements and market expansion. This strategic appointment is anticipated to provide the board with fresh insights that align with both the company’s operational strategies and its commitment to enhancing patient care techniques.

With a growing presence in the medical technology landscape, Perimeter continues to pave the way for groundbreaking solutions that underscore the importance of marrying technology with operational excellence. With the addition of experts like Michelle Caron, the company stands better equipped to tackle the complexities of modern healthcare environments and deliver meaningful impacts on surgical outcomes.